Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Development > SPI-014

SPI-014Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

A potent and selective second generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology

Target Indications

  • Hyperphosphatemia in End Stage Renal Disease (ESRD).
  • Hyperphosphatemia in earlier stages of CKD

Route of Administration

  • Oral tablet

Mode of Action

SPI-014 binds to phosphates and forms an insoluable lanthanum phosphate complex which is expected to reduce serum phosphate levels in ESRD patients.

Status

  • Phase 1

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

More on SPI-014Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Scanning Electron Micrograph (SEM) of SPI-014

SPI-014

Chronic Kidney Disease

According to the National Kidney Foundation, there are an estimated 26 million adults suffering from CKD in the US. Of these CKD patients, approximately 400,000 patients are at stage 4 and approximately 660,000 are at Stage 5 (ESRD). The incidence of ESRD is increasing at approximately 6% per year. Approximately 70% of ESRD patients have hyperphosphatemia.

In 2010, sales of phosphate binding agents are expected to increase to over $1B.